Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth
Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth
复制标题
DOI：
10.1097/01.cji.0000175494.13476.56
复制
发表时间：
2006-01-01
影响因子：
3.9
通讯作者：
Khleif, SN
中科院分区：
文献类型：
--
作者：
Dong, YJ;Qian, JH;Khleif, SN
血管内皮生长因子受体 2 (VEGFR2/KDR) 在肿瘤相关的血管生成和血管化中发挥着至关重要的作用。已经确定抗 VEGFR2 的单克隆抗体可以抑制血管生成。在这项研究中，从小鼠 KDR 中鉴定出两个自然加工的 CD8 T 细胞表位（VILTNPISM 和 FSNSTNDILI）。靶向内皮细胞的细胞毒性 T 淋巴细胞可以通过 KDR2 和 KDR3 Elispots 或主要组织相容性复合物 I 类四聚体染色直接监测。在小鼠模型中，用这两种肽进行免疫可有效减少血管生成并抑制肿瘤生长。因此，单独使用KDR肽或与其他抗血管生成剂组合进行疫苗接种可以提供抑制肿瘤生长的新型免疫疗法。
Vascular endothelial growth factor receptor 2 (VEGFR2/KDR) plays a crucial role in tumor-associated angiogenesis and vascularization. It has been established that monoclonal antibodies against VEGFR2 can inhibit angiogenesis. In this study, two naturally processed CD8 T-cell epitopes (VILTNPISM and FSNSTNDILI) were identified from murine KDR. Cytotoxic T lymphocytes targeting endothelial cells could be directly monitored by KDR2 and KDR3 Elispots or major histocompatibility complex class I tetramer staining. Immunization with these two peptides effectively reduced angiogenesis and inhibited tumor growth in mouse models. Thus, vaccination with KDR peptides alone or in combination with other anti-angiogenesis agents may afford a novel immunotherapy for inhibition of tumor growth.